OTCMKTS:KIADF Kiadis Pharma (KIADF) Stock Price, News & Analysis → War Over Taiwan? Protect Your Wealth NOW (From Behind the Markets) (Ad) Free KIADF Stock Alerts $6.41 0.00 (0.00%) (As of 07/21/2021) Add Share Share Today's Range$6.41▼$6.4150-Day Range$6.41▼$6.4152-Week Range$1.72▼$6.55VolumeN/AAverage Volume1,800 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Kiadis Pharma alerts: Email Address Ad Behind the MarketsWar Over Taiwan? Protect Your Wealth NOWWith tensions rapidly escalating, Taiwan could provide the spark at any moment. Don't let your financial future get caught in the crossfire unprepared.Access my report now >>> About Kiadis Pharma Stock (OTCMKTS:KIADF)Kiadis Pharma N.V., a biopharmaceutical company, develops cell-based immunotherapy products in the field of blood building system. The company develops K-NK002 as an adjunctive immunotherapeutic, which is in Phase II clinical trials for blood cancer patients undergoing a haploidentical HSCT with the post-transplant cyclophosphamide (PTCy) protocol; and K-NK003, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia relapse/refractory (AML R/R). The company's preclinical stage product include K-NK00X, a NK-cell therapy candidate for the treatment of various solid tumors. It has a collaboration agreement with Harbour BioMed, Utrecht University, Erasmus Medical Center, and Viroclinics-DDL for the development of a combination of a monoclonal antibody and natural killer cells as a treatment for COVID-19. Kiadis Pharma N.V. was founded in 1997 and is headquartered in Amsterdam, the Netherlands.Read More KIADF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart KIADF Stock News HeadlinesApril 7, 2024 | seekingalpha.comLTRN Lantern Pharma Inc.January 31, 2024 | forbes.comAlnylam PharmaceuticalsApril 26, 2024 | Behind the Markets (Ad)War Over Taiwan? Protect Your Wealth NOWWith tensions rapidly escalating, Taiwan could provide the spark at any moment. Don't let your financial future get caught in the crossfire unprepared.July 20, 2023 | nytimes.comTraveling With Little Kids Can Be Tough. The Right Gear Can Help.June 27, 2023 | travel.usnews.comThe Best Kids Luggage: 9 Picks for 2023January 25, 2023 | seekingalpha.com22nd Century Group submits filing to FDA for CBD active pharmaceutical ingredientSee More Headlines Receive KIADF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kiadis Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorN/A Industry N/A Sub-IndustryN/A Current SymbolOTCMKTS:KIADF CUSIPN/A CIKN/A Webwww.kiadis.com Phone31 20 240 5250FaxN/AEmployees103Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesMr. Arthur Lahr (Age 53)CEO & Member of the Management Board Comp: $430.94kMr. Paul van HagenSr. VP of Fin.Mr. Dirk De NaeyerChief Operations OfficerDr. Robert Friesen Ph.D.Chief Scientific OfficerMaryann CiminoSr. Mang. of Investor Relations & Corp. AffairsMs. Margot Hoppe (Age 57)Gen. Counsel & Corp. Sec. Dr. Andrew Seth Sandler M.D. (Age 56)Chief Medical Officer Ms. Amy B. SullivanChief Strategy OfficerMs. Martine NolanSr. VP of QualityDr. Raymond Barlow B.Sc. (Age 52)M.B.A., B.Sc. (Hons), Ph.D., MBA, Chief Bus. Officer More Executives KIADF Stock Analysis - Frequently Asked Questions How have KIADF shares performed in 2024? Kiadis Pharma's stock was trading at $6.41 at the beginning of 2024. Since then, KIADF shares have increased by 0.0% and is now trading at $6.41. View the best growth stocks for 2024 here. How do I buy shares of Kiadis Pharma? Shares of KIADF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:KIADF) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTrump is sounding the alarmPreserve GoldRich Dad Poor Dad Author Shocks Millions With 2024 Crash WarningAmerican Hartford Gold Group Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kiadis Pharma Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
